*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Cofoe Medical Technology Co., Ltd.
# 可孚醫療科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1187)**

## 2026 THIRD QUARTERLY REPORT

This announcement is made by Cofoe Medical Technology Co., Ltd. (the "**Company**") pursuant to the disclosure obligations under Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (as defined in the Listing Rules).

Set out below is the Company's 2026 third quarterly report for the three months ended September 30, 2026 (the "**reporting period**"), and the financial information contained herein has been prepared in accordance with the China Accounting Standards for Business Enterprises and has not been audited. Unless otherwise stated, the currency unit of the quarterly report is RMB.

This announcement is prepared in both Chinese and English. In the event of any discrepancy between the Chinese and English versions, the Chinese version shall prevail.

**IMPORTANT NOTICE:**

1. The board of directors, as well as the directors and senior management, warrant that the contents of this quarterly report are true, accurate, and complete, and contain no false records, misleading statements, or material omissions, and they assume individual and joint legal liability for its contents.

2. The person in charge of the Company, the person in charge of accounting affairs, and the head of the accounting department (accounting supervisor) warrant the truth, accuracy, and completeness of the financial information in this quarterly report.

3. Whether the Q3 financial report has been audited

☐ Yes ✓ No

## I. KEY FINANCIAL DATA

### (I) Key Accounting Data and Financial Indicators

Whether retroactive adjustments or restatements would be made by the Company to the accounting data for the previous years

☐ Yes ✓ No

| | The reporting period | Increase/decrease in the reporting period compared to the same period of previous year | From the beginning of the year to the end of the reporting period | Increase/decrease from the beginning of the year to the end of the reporting period compared to the same period of previous year |
|---|---|---|---|---|
| Operating revenue (RMB) | 1,119,142,998.01 | 24.07% | 3,190,990,989.37 | 33.08% |
| Net profit attributable to shareholders of the listed company (RMB) | 102,980,939.88 | 10.94% | 305,244,714.07 | 17.30% |
| Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (RMB) | 96,926,832.68 | 12.96% | 269,524,480.01 | 21.41% |
| Net cash flows from operating activities (RMB) | – | – | 264,068,007.73 | -55.24% |
| Basic earnings per share (RMB/share) | 0.45 | -2.17% | 1.40 | 9.38% |
| Diluted earnings per share (RMB/share) | 0.45 | -2.17% | 1.38 | 8.66% |
| Weighted average return on net assets | 2.06% | Increased by 0.16 percentage points | 5.87% | Increased by 0.58 percentage points |

| | End of the reporting period | End of last year | Increase/decrease at the end of the reporting period compared to the end of last year |
|---|---|---|---|
| Total assets (RMB) | 7,596,330,054.55 | 6,628,915,230.03 | 14.59% |
| Owners' equity attributable to shareholders of the listed company (RMB) | 5,347,027,752.59 | 4,866,857,736.11 | 9.87% |

**(II) Non-recurring Profit or Loss Items and Amounts**

✓ Applicable ☐ Not applicable

*Unit: RMB*

| Item | Amount for the reporting period | Amount from the beginning of the year to the end of the reporting period | Description |
|---|---|---|---|
| Profit or loss on disposal of non-current assets (including the write-off of the provision for impairment of assets) | -253,247.46 | 346,121.67 | |
| Government grants recognized in current profit or loss (except for those closely related to the Company's normal business operations, in line with national policies, enjoyed according to established standards, and having a continuous impact on the Company's profit or loss) | 4,976,773.43 | 17,783,159.31 | |
| Profit or loss from changes in fair value of financial assets and financial liabilities held by non-financial enterprises, and profit or loss from the disposal of financial assets and financial liabilities, except for effective hedging activities related to the Company's normal business operations | 2,388,857.84 | 23,264,755.55 | |
| Other non-operating income and expenses excluding the above items | 34,746.34 | -309,027.69 | |
| Less: Income tax effect | 1,069,047.45 | 5,286,484.40 | |
| Effect of non-controlling interests (after tax) | 23,975.50 | 78,290.38 | |
| Total | 6,054,107.20 | 35,720,234.06 | – |

Details of other profit or loss items that meet the definition of non-recurring profit or loss:

☐ Applicable ✓ Not applicable

The Company does not have other profit or loss items that meet the definition of non-recurring profit or loss.

Explanation for defining non-recurring profit or loss items listed in the Explanatory Announcement No.1 on Information Disclosure for Companies Publicly Issuing Securities – Non-recurring Profit or Loss as recurring profit or loss items

☐ Applicable ✓ Not applicable

The Company does not have any circumstances where non-recurring profit or loss items listed in the Explanatory Announcement No.1 on Information Disclosure for Companies Publicly Issuing Securities – Non-recurring Profit or Loss are defined as recurring profit or loss items.

## (III) Changes in Major Accounting Data and Financial Indicators and the Reasons

✓ Applicable □ Not applicable

### *1. Changes in the Consolidated Balance Sheet and the reasons*

*Unit: RMB*

| Item | September 30, 2026 | December 31, 2025 | Percentage of change | Reason |
|---|---|---|---|---|
| Monetary funds | 2,704,301,795.77 | 1,421,698,948.31 | 90.22% | Mainly due to the receipt of proceeds from issuance of H shares during the current period |
| Financial assets held for trading | 373,543,935.32 | 1,016,829,270.02 | -63.26% | Mainly due to the maturity of wealth management products during the current period |
| Receivables financing | 15,444,536.75 | 25,043,014.05 | -38.33% | Mainly due to the decrease in Grade A acceptance bills held during the current period |
| Prepayments | 277,963,302.63 | 147,847,688.07 | 88.01% | Mainly due to stocking up on core product categories and the increase in prepayments for goods to suppliers during the current period |
| Non-current assets due within one year | 6,492,451.22 | 2,273,687.62 | 185.55% | Mainly due to the increase in the amount of long-term receivables due within one year during the current period |
| Other investments in equity instruments | 15,230,718.58 | – | 100.00% | Mainly due to the new external equity investment during the current period, which was designated as financial assets at fair value through other comprehensive income |
| Construction in progress | 225,082,312.17 | 138,628,836.57 | 62.36% | Mainly due to the increase in investment in construction in progress for buildings and structures during the current period |
| Development expenditures | 27,751,477.90 | 17,256,536.34 | 60.82% | Mainly due to the increase in capitalised research and development costs during the current period |
| Other non-current assets | 30,294,635.15 | 16,013,425.89 | 89.18% | Mainly due to the payment of equity acquisition consideration during the current period |
| Short-term borrowings | 918,067,197.81 | 574,747,853.12 | 59.73% | Mainly due to the Company's new bank borrowings during the current period to replenish daily working capital and ensure the payment for procurement of goods |

| Item | September 30, 2026 | December 31, 2025 | Percentage of change | Reason |
|---|---|---|---|---|
| Bills payable | 136,006,360.82 | 80,408,238.55 | 69.14% | Mainly due to the increase in commercial bills payable to suppliers during the current period |
| Receipts in advance | 13,383.46 | 233,538.80 | -94.27% | Mainly due to the decrease in rental amounts received in advance during the current period |
| Employee benefits payable | 40,840,284.15 | 58,473,078.53 | -30.16% | Mainly due to the annual performance remuneration accrued at the end of the last year being paid during the current period, which resulted in the remuneration accrued in the current period being lower than the amount paid, and the balance decreased accordingly |
| Taxes payable | 58,832,046.02 | 19,926,312.94 | 195.25% | Mainly due to the increase in value-added tax and income tax payable during the current period |
| Non-current liabilities due within one year | 46,077,814.21 | 183,395,494.54 | -74.88% | Mainly due to the repayment of long-term borrowings due within one year during the current period |
| Other current liabilities | 8,474,445.29 | 13,535,462.57 | -37.39% | Mainly due to the decrease in payables in relation to bills endorsed but not derecognised during the current period |
| Long-term borrowings | 180,000,000.00 | – | 100.00% | Mainly due to new long-term borrowings during the current period |
| Treasury shares | 455,713,377.62 | 140,471,434.28 | 224.42% | Mainly due to the increase in repurchase of the Company's A shares during the current period |
| Accumulated other comprehensive income | -22,558,788.03 | -1,548,497.70 | -1,356.82% | Mainly due to the effect of changes in fair value of other investments in equity instruments during the current period |

## *2. Changes in the Consolidated Income Statement and the reasons*

*Unit: RMB*

| Item | Amount for January to September 2026 | Amount for January to September 2025 | Percentage of change | Reason |
|---|---|---|---|---|
| Operating revenue | 3,190,990,989.37 | 2,397,791,920.73 | 33.08% | Mainly due to the volume growth of core products which drove organic growth during the current period |
| Selling expenses | 1,200,707,488.20 | 815,836,447.67 | 47.18% | Mainly due to increased online product marketing and promotion during the current period, which led to an increase in online promotion expenses |
| Research and development expenses | 79,921,785.54 | 61,091,966.84 | 30.82% | Mainly due to the increase in research and development investment during the current period |
| Finance expenses | 9,560,460.22 | -3,773,642.32 | 353.35% | Mainly due to exchange losses of RMB21.458 million during the current period, with the increase in exchange losses exceeding the increase in interest income |
| Investment income | -8,693,136.47 | 18,180,571.98 | -147.82% | Mainly due to the increase in investment losses recognized on equity investments as well as the decrease in size of wealth management products and decrease in matured investment income during the current period |
| Fair value gains | 22,555,871.71 | 13,885,783.64 | 62.44% | Mainly due to the increase in fair value changes of equity instrument investments during the current period |
| Gains on disposal of assets | 603,787.11 | -695,656.48 | 186.79% | Mainly due to changes in right-of-use assets and termination of lease during the current period, resulting in the recognition of gains or losses on disposal of assets |
| Non-operating income | 2,384,612.66 | 5,897,448.15 | -59.57% | Mainly due to the decrease in the write-off of payables no longer required to be paid and in litigation settlement proceeds received during the current period |

### *3. Changes in the Consolidated Cash Flow Statement and the reasons*

*Unit: RMB*

| Item | Amount for January to September 2026 | Amount for January to September 2025 | Percentage of change | Reason |
|---|---|---|---|---|
| Net cash flows from operating activities | 264,068,007.73 | 589,991,388.19 | -55.24% | Mainly due to the fact that based on its annual business plan and its assessment of market demand for core product categories, the Company increased the procurement of goods, which led to an increase in prepayments for goods to suppliers and an increase in inventory, resulting in an increase in operating cash outflows and a decrease in net operating cash flow for the current period |
| Net cash flows from investing activities | 454,324,535.37 | -166,212,273.98 | 373.34% | Mainly due to the decrease in cash paid for investments in wealth management products and acquisition of subsidiaries during the current period |
| Net cash flows from financing activities | 559,985,117.63 | -349,847,950.86 | 260.07% | Mainly due to the receipt of proceeds from issuance of H shares during the current period |
| Effect of foreign exchange rate changes on cash and cash equivalents | -23,849,499.41 | -2,049,743.68 | -1,063.54% | Mainly due to the receipt of proceeds from issuance of H shares in Hong Kong dollars during the current period, which increased the foreign currency reserves, coupled with the year-on-year depreciation of the US dollar and Hong Kong dollar against the Renminbi at the end of the period |

## II. SHAREHOLDER INFORMATION

### (I) Table of Total Number of Ordinary Shareholders, the Number of Preferred Shareholders with Restored Voting Rights, and the Shareholdings of the Top 10 Shareholders

*Unit: share*

| | | | |
|---|---|---|---|
| **Total number of ordinary shareholders at the end of the reporting period** | 14,972 (including 14,969 holders of A shares and 3 registered holders of H shares) | **Total number of preferred shareholders with restored voting rights at the end of the reporting period (if any)** | 0 |

**Shareholdings of the top 10 shareholders (excluding shares lent through securities refinancing)**

| Name of shareholder | Nature of shareholder | Shareholding percentage | Number of shares held | Number of shares held with selling restrictions | Pledge, marking, or freezing status | |
|---|---|---|---|---|---|---|
| | | | | | Share status | Quantity |
| Changsha Xiezihao Medical Investment Co., Ltd. | Domestic non-state-owned legal person | 37.44% | 88,321,123 | 0 | Pledged | 16,000,000 |
| HKSCC NOMINEES LIMITED | Foreign legal person | 11.45% | 26,999,899 | 0 | Not applicable | 0 |
| Zhang Min | Domestic natural person | 5.14% | 12,114,881 | 9,086,161 | Not applicable | 0 |
| Changsha Keyuan Tongchuang Venture Capital Partnership (Limited Partnership) | Domestic non-state-owned legal person | 5.14% | 12,114,881 | 0 | Not applicable | 0 |
| Zhang Zhiming | Domestic natural person | 3.08% | 7,268,928 | 5,451,696 | Not applicable | 0 |
| Huagai Capital Co., Ltd. – Capital Healthcare Industry (Beijing) Fund (Limited Partnership) | Others | 1.77% | 4,181,840 | 0 | Not applicable | 0 |
| Ningbo Huaige Health Investment Management Partnership (Limited Partnership) – Ningbo Huaige Gongxin Venture Capital Partnership (Limited Partnership) | Others | 1.70% | 4,000,000 | 0 | Not applicable | 0 |
| Nie Juan | Domestic natural person | 1.48% | 3,485,739 | 0 | Not applicable | 0 |
| Basic Pension Insurance Fund Portfolio 2101 | Others | 1.22% | 2,880,365 | 0 | Not applicable | 0 |
| Vision Capital Management Co., Ltd. – Vision China Value Growth No. 16 Private Equity Investment Fund | Others | 0.84% | 1,990,090 | 0 | Not applicable | 0 |

**Shareholdings of the top 10 shareholders of shares without selling restrictions (excluding shares lent through securities refinancing and senior management's locked-in shares)**

| Name of shareholder | Number of shares held without selling restrictions | Type and quantity of shares | |
|---|---|---|---|
| | | Type of shares | Quantity |
| Changsha Xiezihao Medical Investment Co., Ltd. | 85,079,923 | RMB common shares | 85,079,923 |
| | 3,241,200 | Overseas listed foreign shares | 3,241,200 |
| HKSCC NOMINEES LIMITED | 26,999,899 | Overseas listed foreign shares | 26,999,899 |
| Changsha Keyuan Tongchuang Venture Capital Partnership (Limited Partnership) | 12,114,881 | RMB common shares | 12,114,881 |
| Huagai Capital Co., Ltd. – Capital Healthcare Industry (Beijing) Fund (Limited Partnership) | 4,181,840 | RMB common shares | 4,181,840 |
| Ningbo Huaige Health Investment Management Partnership (Limited Partnership) – Ningbo Huaige Gongxin Venture Capital Partnership (Limited Partnership) | 4,000,000 | RMB common shares | 4,000,000 |
| Nie Juan | 3,485,739 | RMB common shares | 3,485,739 |
| Zhang Min | 3,028,720 | RMB common shares | 3,028,720 |
| Basic Pension Insurance Fund Portfolio 2101 | 2,880,365 | RMB common shares | 2,880,365 |
| Vision Capital Management Co., Ltd. – Vision China Value Growth No. 16 Private Equity Investment Fund | 1,990,090 | RMB common shares | 1,990,090 |
| Zhang Zhiming | 1,817,232 | RMB common shares | 1,817,232 |

| | |
|---|---|
| Explanation of the related-party relationship or acting-in-concert relationship among the above shareholders | 1. Zhang Min and Nie Juan are husband and wife and are the actual controllers of the Company.<br>2. Zhang Min and Nie Juan collectively hold 100% of the equity of Xiezihao Medical Investment, Zhang Min is the executive director of Xiezihao Medical Investment, and Nie Juan is the general manager of Xiezihao Medical Investment.<br>3. Zhang Min is the general partner and executive partner of Keyuan Tongchuang, holding 5% of the capital contribution. Nie Juan is a limited partner of Keyuan Tongchuang, holding 55% of the capital contribution. Zhang Zhiming is a limited partner of Keyuan Tongchuang, holding 40% of the capital contribution.<br>4. Apart from the above, the Company is not aware of whether there is any related-party relationship among the other top 10 shareholders. |
| Explanation of the participation of the top 10 shareholders in margin trading and securities lending (if any) | The shareholder, Vision Capital Management Co., Ltd. (遠信(珠海)私募基金管理有限公司) – Vision China Value Growth No.16 Private Equity Investment Fund, holds 1,180,000 Shares of the Company via a general securities account and 810,090 Shares of the Company via a margin trading collateral securities account, with an actual aggregate holding of 1,990,090 Shares of the Company. |

*Note:* At the end of the reporting period, the Company has a special repurchase account–"Special Repurchase Securities Account of Cofoe Medical Technology Co., Ltd." (listed as the 5th shareholder in the register, but not included in the list of the top 10 shareholders). This repurchase account holds 9,792,781 A shares of the Company, accounting for 4.15% of the total share capital.

Participation of shareholders holding more than 5% of shares, the top 10 shareholders, and the top 10 shareholders of tradable shares without selling restrictions in share lending through refinancing

☐ Applicable ✓ Not applicable

Changes in the top 10 shareholders and the top 10 shareholders of tradable shares without selling restrictions compared with the previous period due to lending/return of shares through refinancing

☐ Applicable ✓ Not applicable

**(II) Total Number of Preferred Shareholders and Shareholdings of the Top 10 Preferred Shareholders**

☐ Applicable ✓ Not applicable

## (III) Changes in Shares Subject to Selling Restrictions

✓ Applicable □ Not applicable

*Unit: shares*

| Name of shareholder | Number of shares subject to selling restrictions at the beginning of the period | Number of shares released from selling restrictions during the period | Number of shares subject to new selling restrictions during the period | Number of shares subject to selling restrictions at the end of the period | Reason for selling restrictions | Proposed date of release from selling restrictions |
|---|---|---|---|---|---|---|
| Zhang Min | 9,086,161 | | | 9,086,161 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| Zhang Zhiming | 5,451,696 | | | 5,451,696 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| Xue Xiaoqiao | 65,312 | | 16,250 | 81,562 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| He Bangjie | 65,312 | | 16,250 | 81,562 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| Yu Xiangyu | 29,250 | | | 29,250 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| Chen Wangpeng | 41,437 | | 9,750 | 51,187 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| Ouyang Jie | 43,875 | | | 43,875 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| Zuo Hanqing | 73,937 | | 6,500 | 80,437 | Senior management lock-up | 25% of the shareholding at the end of the previous year will be released from selling restrictions at the beginning of each year |
| Total | 14,856,980 | 0 | 48,750 | 14,905,730 | – | – |

## III. OTHER SIGNIFICANT EVENTS

□ Applicable ✓ Not applicable

## IV. QUARTERLY FINANCIAL STATEMENTS

### (I) Financial Statements

#### *1. Consolidated Balance Sheet*

Prepared by: Cofoe Medical Technology Co., Ltd.

September 30, 2026

*Unit: RMB*

| Item | Closing balance | Opening balance |
|---|---|---|
| **Current assets:** | | |
| Monetary funds | 2,704,301,795.77 | 1,421,698,948.31 |
| Settlement reserves | | |
| Placements with banks and other financial institutions | | |
| Financial assets held for trading | 373,543,935.32 | 1,016,829,270.02 |
| Derivative financial assets | | |
| Bills receivable | 10,913,079.19 | 14,955,203.08 |
| Accounts receivable | 409,565,204.12 | 404,787,366.02 |
| Receivables financing | 15,444,536.75 | 25,043,014.05 |
| Prepayments | 277,963,302.63 | 147,847,688.07 |
| Premiums receivable | | |
| Reinsurance receivables | | |
| Reinsurance contract reserves receivable | | |
| Other receivables | 73,686,441.06 | 59,091,364.80 |
| Including: Interest receivable | | |
| Dividends receivable | | |
| Financial assets purchased under agreements to resell | | |
| Inventories | 832,847,474.17 | 675,498,725.47 |
| Including: Data resource | | |
| Contract assets | | |
| Assets held for sale | | |
| Non-current assets due within one year | 6,492,451.22 | 2,273,687.62 |
| Other current assets | 49,201,655.06 | 67,296,397.04 |
| **Total current assets** | 4,753,959,875.29 | 3,835,321,664.48 |

| Item | Closing balance | Opening balance |
|---|---|---|
| **Non-current assets:** | | |
| Loans and advances | | |
| Debt investments | | |
| Other debt investments | | |
| Long-term receivables | 4,555,033.34 | 4,932,150.22 |
| Long-term equity investments | 274,753,100.26 | 237,335,163.60 |
| Other investments in equity instruments | 15,230,718.58 | |
| Other non-current financial assets | 5,961,500.00 | 5,961,500.00 |
| Investment properties | 30,884,350.97 | 27,962,154.04 |
| Fixed assets | 1,401,671,121.63 | 1,480,098,923.28 |
| Construction in progress | 225,082,312.17 | 138,628,836.57 |
| Productive biological assets | | |
| Oil & gas assets | | |
| Right-of-use assets | 104,926,120.27 | 131,585,717.77 |
| Intangible assets | 271,570,864.75 | 278,125,879.79 |
| Including: Data resource | | |
| Development expenditures | 27,751,477.90 | 17,256,536.34 |
| Including: Data resource | | |
| Goodwill | 368,912,266.63 | 368,912,266.63 |
| Long-term prepaid expenses | 38,409,571.66 | 46,255,941.89 |
| Deferred income tax assets | 42,367,105.95 | 40,525,069.53 |
| Other non-current assets | 30,294,635.15 | 16,013,425.89 |
| **Total non-current assets** | 2,842,370,179.26 | 2,793,593,565.55 |
| **Total assets** | 7,596,330,054.55 | 6,628,915,230.03 |

| Item | Closing balance | Opening balance |
|---|---|---|
| **Current liabilities:** | | |
| Short-term borrowings | 918,067,197.81 | 574,747,853.12 |
| Borrowings from the Central Bank | | |
| Placements from banks and other financial institutions | | |
| Financial liabilities held for trading | | |
| Derivative financial liabilities | | |
| Bills payable | 136,006,360.82 | 80,408,238.55 |
| Accounts payable | 608,810,905.55 | 558,637,328.21 |
| Receipts in advance | 13,383.46 | 233,538.80 |
| Contract liabilities | 21,746,893.96 | 29,073,453.36 |
| Financial assets sold for repurchase | | |
| Receipt of deposits and deposits from other banks | | |
| Deposit for securities trading brokerage | | |
| Deposit for securities underwriting brokerage | | |
| Employee benefits payable | 40,840,284.15 | 58,473,078.53 |
| Taxes payable | 58,832,046.02 | 19,926,312.94 |
| Other payables | 77,518,203.06 | 70,335,081.89 |
| Including: Interest payable | | |
| Dividends payable | 16,200,000.00 | |
| Fees and commissions payable | | |
| Reinsurance accounts payable | | |
| Liabilities held for sale | | |
| Non-current liabilities due within one year | 46,077,814.21 | 183,395,494.54 |
| Other current liabilities | 8,474,445.29 | 13,535,462.57 |
| **Total current liabilities** | 1,916,387,534.33 | 1,588,765,842.51 |

| Item | Closing balance | Opening balance |
|---|---|---|
| **Non-current liabilities:** | | |
| Insurance contract reserves | | |
| Long-term borrowings | 180,000,000.00 | |
| Bonds payable | | |
| Including: Preferred shares | | |
| Perpetual bonds | | |
| Lease liabilities | 54,222,373.82 | 68,036,539.67 |
| Long-term payables | | |
| Long-term employee benefits payable | 2,698,522.03 | 2,881,777.87 |
| Provisions | | |
| Deferred income | 53,749,202.41 | 58,592,909.47 |
| Deferred income tax liabilities | 8,072,060.72 | 7,749,673.09 |
| Other non-current liabilities | | |
| **Total non-current liabilities** | 298,742,158.98 | 137,260,900.10 |
| **Total liabilities** | 2,215,129,693.31 | 1,726,026,742.61 |
| **Owners' equity:** | | |
| Share capital | 235,897,000.00 | 208,897,000.00 |
| Other equity instruments | | |
| Including: Preferred shares | | |
| Perpetual bonds | | |
| Capital reserves | 4,791,551,385.72 | 3,925,689,395.44 |
| Less: Treasury shares | 455,713,377.62 | 140,471,434.28 |
| Accumulated other comprehensive income | -22,558,788.03 | -1,548,497.70 |
| Specialised reserves | | |
| Surplus reserve | 114,262,970.70 | 104,546,000.00 |
| General risk provision | | |
| Retained earnings | 683,588,561.82 | 769,745,272.65 |
| **Total owners' equity attributable to equity holders of the parent** | 5,347,027,752.59 | 4,866,857,736.11 |
| Non-controlling interests | 34,172,608.65 | 36,030,751.31 |
| **Total owners' equity** | 5,381,200,361.24 | 4,902,888,487.42 |
| **Total liabilities and owners' equity** | 7,596,330,054.55 | 6,628,915,230.03 |

| *Legal Representative:* | *Person in Charge of Accounting Affairs:* | *Head of Accounting Department:* |
|---|---|---|
| **ZHANG Min** | **CHEN Wangpeng** | **SHEN Pei** |

***2. Consolidated Income Statement from the beginning of the year to the end of the reporting period***

*Unit: RMB*

| Item | | Amount for January to September 2026 | Amount for January to September 2025 |
|---|---|---|---|
| **I.** | **Total operating revenue** | 3,190,990,989.37 | 2,397,791,920.73 |
| | Including: Operating revenue | 3,190,990,989.37 | 2,397,791,920.73 |
| | Interest income | | |
| | Insurance premiums earned | | |
| | Handling fees and commission income | | |
| **II.** | **Total operating costs** | 2,852,162,092.66 | 2,140,937,840.58 |
| | Including: Cost of sales | 1,396,494,874.36 | 1,118,462,515.90 |
| | Interest expenses | | |
| | Handling fees and commission expenses | | |
| | Surrender value | | |
| | Net claims paid | | |
| | Net amount of insurance reserves provided | | |
| | Insurance policy dividend paid | | |
| | Reinsurance expenses | | |
| | Taxes and surcharges | 29,954,472.60 | 26,136,687.99 |
| | Selling expenses | 1,200,707,488.20 | 815,836,447.67 |
| | Administrative expenses | 135,523,011.74 | 123,183,864.50 |
| | Research and development expenses | 79,921,785.54 | 61,091,966.84 |
| | Finance expenses | 9,560,460.22 | -3,773,642.32 |
| | Including: Interest expenses | 13,795,537.93 | 11,014,162.32 |
| | Interest income | 29,339,321.16 | 18,284,724.08 |
| | Add: Other income | 33,445,208.60 | 42,484,969.26 |
| | Investment income (loss shall be stated as "-") | -8,693,136.47 | 18,180,571.98 |
| | Including: Income from investments in associates and joint ventures | -9,658,939.33 | 1,366,417.26 |
| | Gains on derecognition of financial assets measured at amortized cost | | |
| | Foreign exchange gain (loss shall be stated as "-") | | |
| | Net gain on exposure hedging (loss shall be stated as "-") | | |
| | Fair value gains (loss shall be stated as "-") | 22,555,871.71 | 13,885,783.64 |
| | Credit impairment losses (loss shall be stated as "-") | -1,228,124.74 | -1,146,418.95 |
| | Impairment losses on assets (loss shall be stated as "-") | -19,560,021.21 | -27,752,399.95 |
| | Gains on disposal of assets (loss shall be stated as "-") | 603,787.11 | -695,656.48 |

| Item | | | Amount for January to September 2026 | Amount for January to September 2025 |
|---|---|---|---|---|
| **III.** | **Operating profit (loss shall be stated as "-")** | | 365,952,481.71 | 301,810,929.65 |
| | Add: Non-operating income | | 2,384,612.66 | 5,897,448.15 |
| | Less: Non-operating expenses | | 2,951,305.76 | 3,531,274.67 |
| **IV.** | **Total profit (total loss shall be stated as "-")** | | 365,385,788.61 | 304,177,103.13 |
| | Less: Income tax expenses | | 58,798,117.40 | 44,669,457.40 |
| **V.** | **Net profit (net loss shall be stated as "-")** | | 306,587,671.21 | 259,507,645.73 |
| | (I) | Classified by continuity of operations | | |
| | | 1. Net profit from continuing operations (net loss shall be stated as "-") | 306,587,671.21 | 259,507,645.73 |
| | | 2. Net profit from discontinued operations (net loss shall be stated as "-") | | |
| | (II) | Classified by ownership of the equity | | |
| | | 1. Net profit attributable to shareholders of the parent (net loss shall be stated as "-") | 305,244,714.07 | 260,217,303.07 |
| | | 2. Non-controlling interest profit or loss (net loss shall be stated as "-") | 1,342,957.14 | -709,657.34 |
| **VI.** | **Other comprehensive income, net of tax** | | -24,672,738.89 | 643,588.10 |
| | Other comprehensive income attributable to the owners of the parent, net of tax | | -21,010,290.33 | 563,775.39 |
| | (I) | Other comprehensive income that may not be reclassified to profit or loss | -15,840,206.57 | |
| | | 1. Changes arising from remeasurement under defined benefit plan | | |
| | | 2. Other comprehensive income that may not be transferred to profit or loss under equity method | | |
| | | 3. Change in fair value of investments in other equity instruments | -15,840,206.57 | |
| | | 4. Change in fair value of the Company's own credit risk | | |
| | | 5. Others | | |

| Item | | | Amount for January to September 2026 | Amount for January to September 2025 |
|---|---|---|---|---|
| | (II) | Other comprehensive income that may be reclassified to profit or loss | -5,170,083.76 | 563,775.39 |
| | | 1. Other comprehensive income that may be reclassified to profit or loss under equity method | | |
| | | 2. Change in fair value of other debt investments | | |
| | | 3. Amount of financial asset reclassification included in other comprehensive income | | |
| | | 4. Credit impairment allowance of other debt investments | | |
| | | 5. Cash flow hedging reserve | | |
| | | 6. Exchange differences on translation of foreign currency financial statements | -5,170,083.76 | 563,775.39 |
| | | 7. Others | | |
| | Other comprehensive income, net of tax, attributable to non-controlling interests | | -3,662,448.56 | 79,812.71 |
| **VII.** | **Total comprehensive income** | | 281,914,932.32 | 260,151,233.83 |
| | (I) | Total comprehensive income attributable to the owners of the parent | 284,234,423.74 | 260,781,078.46 |
| | (II) | Total comprehensive income attributable to non-controlling interests | -2,319,491.42 | -629,844.63 |
| **VIII.** | **Earnings per share:** | | | |
| | (I) | Basic earnings per share | 1.40 | 1.28 |
| | (II) | Diluted earnings per share | 1.38 | 1.27 |

For business combination under common control occurred during the current period, the net profit realised by the combined party before the combination was RMB0, and the net profit realised by the combined party in the previous period was RMB0.

| *Legal Representative:* | *Person in Charge of Accounting Affairs:* | *Head of Accounting Department:* |
|---|---|---|
| **ZHANG Min** | **CHEN Wangpeng** | **SHEN Pei** |

***3. Consolidated Cash Flow Statement from the beginning of the year to the end of the reporting period***

*Unit: RMB*

| Item | | Amount for January to September 2026 | Amount for January to September 2025 |
|---|---|---|---|
| **I.** | **Cash flows from operating activities:** | | |
| | Cash received from sales of goods or rendering of services | 3,265,431,676.84 | 2,498,112,040.76 |
| | Net increase in customer deposits and placements from banks and other financial institutions | | |
| | Net increase in borrowings from the Central Bank | | |
| | Net increase in borrowings from other financial institutions | | |
| | Cash received from premiums of original insurance contracts | | |
| | Net cash received from reinsurance business | | |
| | Net increase in policyholders' deposits and investment funds | | |
| | Cash received from interest, handling fees, and commissions | | |
| | Net increase in borrowings from banks and other financial institutions | | |
| | Net increase in funds from repurchase agreements | | |
| | Net cash received from securities brokerage | | |
| | Refunds of taxes and surcharges | 15,568,486.48 | 6,876,263.90 |
| | Other cash received relating to operating activities | 115,340,970.87 | 131,316,723.21 |
| Subtotal of cash inflows from operating activities | | 3,396,341,134.19 | 2,636,305,027.87 |
| | Cash paid for purchasing goods and receiving services | 1,352,039,475.42 | 879,005,212.06 |
| | Net increase in loans and advances to customers | | |
| | Net increase in deposits with the Central Bank and placements with banks and other financial institutions | | |
| | Cash paid for claims under original insurance contracts | | |
| | Net increase in placements with banks and other financial institutions | | |
| | Cash paid for interest, handling fees, and commissions | | |
| | Cash paid for policy dividends | | |
| | Cash paid to and on behalf of employees | 513,719,183.15 | 460,308,253.44 |
| | Payments of taxes and surcharges | 171,110,735.71 | 163,166,593.65 |
| | Other cash paid relating to operating activities | 1,095,403,732.18 | 543,833,580.53 |
| Subtotal of cash outflows from operating activities | | 3,132,273,126.46 | 2,046,313,639.68 |
| Net cash flows from operating activities | | 264,068,007.73 | 589,991,388.19 |

| Item | | Amount for January to September 2026 | Amount for January to September 2025 |
|---|---|---|---|
| **II.** | **Cash flows from investing activities:** | | |
| | Cash received from disposal of investments | 1,150,821,898.85 | 1,274,344,499.00 |
| | Cash received from returns on investments | 12,616,049.83 | 21,314,112.75 |
| | Net cash received from disposals of fixed assets, intangible assets and other long-term assets | 1,452,940.43 | 8,661,081.62 |
| | Net cash receipts from the disposal of subsidiaries and other business units | | 6,861,725.02 |
| | Other cash received relating to investing activities | | 539,362.45 |
| Subtotal of cash inflows from investing activities | | 1,164,890,889.11 | 1,311,720,780.84 |
| | Cash paid to acquire fixed assets, intangible assets and other long-term assets | 123,444,107.73 | 160,657,696.53 |
| | Cash paid to acquire investments | 577,122,246.01 | 1,184,147,380.59 |
| | Net increase in pledged loans | | |
| | Net cash paid to acquire subsidiaries and other business units | | 133,127,977.70 |
| | Other cash paid relating to investing activities | 10,000,000.00 | |
| Subtotal of cash outflows from investing activities | | 710,566,353.74 | 1,477,933,054.82 |
| Net cash flows from investing activities | | 454,324,535.37 | -166,212,273.98 |

| Item | | Amount for January to September 2026 | Amount for January to September 2025 |
|---|---|---|---|
| **III.** | **Cash flows from financing activities:** | | |
| | Cash received from capital contributions | 910,929,239.53 | 700,000.00 |
| | Including: Cash received by subsidiaries from minority shareholders' investment | 1,000,000.00 | 700,000.00 |
| | Cash received from borrowings | 1,864,954,282.60 | 1,023,077,709.36 |
| | Other cash received relating to financing activities | | 112,861,632.21 |
| Subtotal of cash inflows from financing activities | | 2,775,883,522.13 | 1,136,639,341.57 |
| | Cash paid for repayment of debts | 1,470,977,225.46 | 951,002,360.38 |
| | Cash paid for distribution of dividends or profits and for interest expenses | 372,224,161.75 | 367,040,359.37 |
| | Including: Dividends or profits paid by subsidiaries to minority shareholders | 385,242.41 | |
| | Other cash paid relating to financing activities | 372,697,017.29 | 168,444,572.68 |
| Subtotal of cash outflows from financing activities | | 2,215,898,404.50 | 1,486,487,292.43 |
| Net cash flows from financing activities | | 559,985,117.63 | -349,847,950.86 |
| **IV.** | **Effect of foreign exchange rate changes on cash and cash equivalents** | -23,849,499.41 | -2,049,743.68 |
| **V.** | **Net increase in cash and cash equivalents** | 1,254,528,161.32 | 71,881,419.67 |
| | Add: Cash and cash equivalents at the beginning of the reporting period | 1,294,575,300.70 | 1,139,986,138.54 |
| **VI.** | **Cash and cash equivalents at the end of the reporting period** | 2,549,103,462.02 | 1,211,867,558.21 |

**(II) Adjustments to Relevant Items of the Financial Statements at the Beginning of the Year of First-Time Adoption of New Accounting Standards from 2026**

☐ Applicable ✓ Not applicable

**(III) Audit Report**

Whether the Q3 financial report has been audited

☐ Yes ✓No

The Q3 financial report of the Company has not been audited.

By Order of the Board
**Cofoe Medical Technology Co., Ltd.**
**ZHANG Min**
*Executive Director and Chairman of the Board*

Hong Kong, October 29, 2026

*As at the date of this announcement, the Board of the Company comprises (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive Directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive Directors.*